Johnson & Johnson Stock Drops 120% in Trading Volume Ranking 65th Despite Promising Clinical Trial Results

On June 16, 2025, Johnson & Johnson (JNJ) experienced a decline of 1.20% in its stock price, with a trading volume of 10.90 billion, ranking 65th in the day's market activity.

Johnson & Johnson recently announced promising results from its Phase 2 RedirecTT-1 study, which evaluated an investigational combination of first-in-class bispecifics. The study demonstrated a high overall response rate of 78.9% through dual targeting of GPRC5D and BCMA. This dual-targeting approach showed deep responses, indicating the potential efficacy of the therapy.

Additionally, a Phase 1b study highlighted the promising safety profile of a novel dual-targeting CD19/CD20 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma. The therapy elicited a treatment response in up to 100% of dosed patients, further supporting its potential as a therapeutic option.

At the European Hematology Association (EHA) 2025 Congress, data from a phase 1b clinical trial evaluating Johnson & Johnson’s JNJ-90014496, a CD19 and CD20-directed bispecific chimeric antigen receptor (CAR) T-cell therapy, were presented. The study reported an overall response rate (ORR) of 100% in the group that received the recommended phase 2 dose, with a complete remission (CR) rate of 80% in patients with only one prior line of therapy. The therapy was well-tolerated, with no grade 3 or 4 cytokine release syndrome (CRS) events in the recommended phase 2 dose group.